Boston Family Office’s Thermo Fisher Scientific TMO Stock Holding History

Boston Family Office’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.8M	Buy	40,308 +199	+0.5%	+$108K	1.32%	21
2025 Q4	$23.2M	Sell	40,109 -875	-2%	-$495K	1.47%	17
2025 Q3	$19.9M	Sell	40,984 -197	-0.5%	-$91.7K	1.26%	26
2025 Q2	$16.7M	Buy	41,181 +1,182	+3%	+$494K	1.11%	27
2025 Q1	$19.9M	Sell	39,999 -175	-0.4%	-$94.8K	1.41%	23
2024 Q4	$20.9M	Sell	40,174 -323	-0.8%	-$178K	1.44%	23
2024 Q3	$25.1M	Buy	40,497 +269	+0.7%	+$159K	1.7%	17
2024 Q2	$22.2M	Buy	40,228 +1,779	+5%	+$1.02M	1.6%	21
2024 Q1	$22.3M	Buy	38,449 +70	+0.2%	+$39.3K	1.61%	18
2023 Q4	$20.4M	Buy	38,379 +716	+2%	+$347K	1.53%	22
2023 Q3	$19.1M	Sell	37,663 -39	-0.1%	-$20.8K	1.56%	18
2023 Q2	$19.7M	Buy	37,702 +22	+0.1%	+$11.9K	1.51%	19
2023 Q1	$21.7M	Sell	37,680 -1,081	-3%	-$609K	1.74%	15
2022 Q4	$21.3M	Sell	38,761 -1,253	-3%	-$664K	1.77%	12
2022 Q3	$20.3M	Buy	40,014 +2,713	+7%	+$1.52M	1.8%	11
2022 Q2	$20.3M	Buy	37,301 +696	+2%	+$383K	1.69%	13
2022 Q1	$21.6M	Sell	36,605 -792	-2%	-$455K	1.54%	17
2021 Q4	$25M	Sell	37,397 -248	-0.7%	-$155K	1.62%	16
2021 Q3	$21.5M	Buy	37,645 +292	+0.8%	+$160K	1.56%	17
2021 Q2	$18.8M	Buy	37,353 +106	+0.3%	+$50K	1.34%	20
2021 Q1	$17.1M	Sell	37,247 -246	-0.7%	-$117K	1.28%	21
2020 Q4	$17.5M	Buy	37,493 +30	+0.1%	+$14.1K	1.34%	19
2020 Q3	$16.5M	Sell	37,463 -198	-0.5%	-$81.8K	1.5%	17
2020 Q2	$13.6M	Buy	37,661 +876	+2%	+$294K	1.33%	18
2020 Q1	$10.4M	Buy	36,785 +203	+0.6%	+$64K	1.23%	25
2019 Q4	$11.9M	Sell	36,582 -227	-0.6%	-$68.8K	1.13%	28
2019 Q3	$10.7M	Sell	36,809 -37	-0.1%	-$10.6K	1.11%	32
2019 Q2	$10.8M	Buy	36,846 +228	+0.6%	+$62.8K	1.12%	30
2019 Q1	$10M	Buy	36,618 +5,029	+16%	+$1.25M	1.08%	34
2018 Q4	$7.07M	Buy	31,589 +3,495	+12%	+$820K	0.88%	42
2018 Q3	$6.86M	Buy	28,094 +2,824	+11%	+$650K	0.72%	48
2018 Q2	$5.23M	Buy	25,270 +1,297	+5%	+$275K	0.59%	58
2018 Q1	$4.95M	Sell	23,973 -347	-1%	-$72.8K	0.56%	63
2017 Q4	$4.62M	Buy	24,320 +1,453	+6%	+$278K	0.51%	68
2017 Q3	$4.33M	Buy	22,867 +805	+4%	+$146K	0.49%	68
2017 Q2	$3.85M	Buy	22,062 +2,082	+10%	+$350K	0.46%	72
2017 Q1	$3.07M	Buy	19,980 +1,115	+6%	+$170K	0.38%	81
2016 Q4	$2.66M	Buy	18,865 +100	+0.5%	+$14.7K	0.35%	86
2016 Q3	$2.98M	Sell	18,765 -350	-2%	-$53.9K	0.39%	78
2016 Q2	$2.82M	Sell	19,115 -960	-5%	-$142K	0.37%	82
2016 Q1	$2.84M	Buy	20,075 +1,075	+6%	+$144K	0.37%	82
2015 Q4	$2.69M	Sell	19,000 -215	-1%	-$28.7K	0.37%	82
2015 Q3	$2.35M	Sell	19,215 -5	-0%	-$651	0.33%	91
2015 Q2	$2.49M	Sell	19,220 -445	-2%	-$58K	0.31%	95
2015 Q1	$2.64M	Buy	19,665 +535	+3%	+$69K	0.33%	92
2014 Q4	$2.4M	Buy	19,130 +80	+0.4%	+$9.73K	0.3%	95
2014 Q3	$2.32M	Sell	19,050 -210	-1%	-$25.5K	0.3%	96
2014 Q2	$2.27M	Buy	19,260 +150	+0.8%	+$17.7K	0.29%	99
2014 Q1	$2.3M	Sell	19,110 -2,190	-10%	-$260K	0.31%	93
2013 Q4	$2.37M	Buy	21,300 +665	+3%	+$66.1K	0.31%	91
2013 Q3	$1.9M	Sell	20,635 -75	-0.4%	-$6.78K	0.27%	98
2013 Q2	$1.75M	Buy	+20,710	New	+$1.72M	0.27%	98

Other funds holding TMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boston Family Office's TMO Position: Q1 2026 in Review

Boston Family Office increased its Thermo Fisher Scientific (TMO) stake by 0.5% in Q1 2026, buying an estimated $108K and bringing the position to 40,308 shares worth $19.8M. The position accounts for 1.32% of the portfolio, ranked #21.

Boston Family Office first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.1M in Q3 2024. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

Boston Family Office held 40,308 shares of Thermo Fisher Scientific worth $19.8M as of Q1 2026.
Boston Family Office bought 199 Thermo Fisher Scientific shares in Q1 2026, an estimated $108K.
Thermo Fisher Scientific made up 1.32% of Boston Family Office's portfolio in Q1 2026, its #21 holding.
Boston Family Office first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
Boston Family Office's Thermo Fisher Scientific position peaked at $25.1M in Q3 2024.
2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Boston Family Office's 13F filing for Q1 2026, filed 13 May 2026.